[EN] BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS PAR HÉTÉROARYLE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2018013770A1
公开(公告)日:2018-01-18
Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
Oxy-Allyl Cation Catalysis: An Enantioselective Electrophilic Activation Mode
作者:Chun Liu、E. Zachary Oblak、Mark N. Vander Wal、Andrew K. Dilger、Danielle K. Almstead、David W. C. MacMillan
DOI:10.1021/jacs.5b13041
日期:2016.2.24
enantioselective conversion of racemic α-tosyloxy ketones to optically enriched α-indolic carbonyls has been accomplished using a new amino alcohol catalyst in the presence of electron-rich indole nucleophiles. Kineticstudies reveal that the rate-determining step in this S(N)1 pathway is the catalyst-mediated α-tosyloxy ketone deprotonation step to form an enantiodiscriminant oxy-allyl cation prior to
This invention relates to compounds of the formula
wherein R
1
to R
9
are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as diabetes, particularly type 2 diabetes, and other metabolic disorders.
[EN] 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS<br/>[FR] COMPOSÉS DE 1,4,5,6-TÉTRAHYDRO-PYRIMIDIN-2-YLAMINE
申请人:HOFFMANN LA ROCHE
公开号:WO2012019966A1
公开(公告)日:2012-02-16
This invention relates to compounds of the formula wherein R1 to R9 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as diabetes, particularly type 2 diabetes, and other metabolic disorders.